[ad_1]
Illustrative image. (Photo / File)
Havana, October 24 (RHC) Cuban scientists badyze new uses of the therapeutic Cimavax-efg lung cancer vaccine, which has shown promising results in the fight against this disease in which countries like the United States are interested.
In this regard, the Granma newspaper published Wednesday that the Center for Molecular Immunology (CIM) was badyzing the effects of using Cimavax in combination with other drugs licensed for cancer Lung, Opportunity of Use
Tania Crombet, a researcher at the ICM, quoted as well, argued that the vaccine – called "therapeutic" because it does not cure cancer but improves the clinical status of the patients and their quality of life – recalled that the drug was injected intramuscularly and that its high level of safety facilitated its use at the primary health care level Up to now, Cimavax , which is applied in advanced cases of non-small cell lung cancer, has been used in more than 5,000 Cuban patients with "promising" results, according to the ICD.
The vaccine was registered in Cuba in 2008 and now has a health registry in Argentina, Colombia, Peru, Paraguay, Bosnia and Herzegovina and Kazakhstan, as well as two medical patents. invention, one of which will be valid until 2028 in 80 countries. 19659004] Clinical studies are underway with the vaccine in institutions in Europe, Asia and the United States, where an alliance between the CIM and the Roswell Park Cancer Institute (New York) was recently announced to create the first company biotechnology. Mixed between the United States and Cuba.
The new company, named Innovative Immunotherapy Alliance (IIA), based in the island, will develop drugs and cancer treatments, then send them to USA
This initiative will also allow Roswell Park to have access to four drugs currently approved for use in other countries, including Cimavax, whose efficacy is being studied at this scientific facility for two years.
Source link
